Hypothyroidism can turn into hyperthyroidism, though it happens far less often than most people assume. The most recognized route involves autoimmune thyroid disease, where the immune system’s attack on the thyroid gland shifts character and begins stimulating it instead of destroying it. Other pathways exist too, from medication dosing errors to iodine exposure to cancer immunotherapy, and the picture gets more interesting when you realize some patients swing back and forth between the two states over months or years.
How Hashimoto’s Can Become Graves’ Disease
Hashimoto’s thyroiditis and Graves’ disease sit on opposite ends of the autoimmune thyroid spectrum. In Hashimoto’s, the immune system attacks and gradually destroys thyroid tissue, leading to underactive function. In Graves’ disease, a different set of antibodies latches onto the TSH receptor and forces the gland to overproduce hormones. What surprises many patients is that both conditions share autoimmune roots, and the immune system’s behavior can change direction.
The shift hinges on which antibodies dominate. A person with Hashimoto’s typically has high levels of thyroid peroxidase antibodies (anti-TPO) and thyroglobulin antibodies (anti-Tg), which drive tissue destruction. But if the immune system begins producing thyroid-stimulating antibodies (TSAb) or TSH receptor antibodies (TRAb) in sufficient quantity, those stimulating signals can overpower the destructive ones, effectively converting hypothyroidism into hyperthyroidism. One documented case showed TRAb surging to 28 IU/L, well above the normal threshold of less than 0.10 IU/L, marking a clear transition from Hashimoto’s to Graves’ disease.1Journal of the Endocrine Society. MON-428 From Hashimoto’s Thyroiditis to Graves’ Disease: Autoimmune Thyroid Disease, a Dynamic Spectrum
A study examining this conversion found that it can occur at almost any point after someone develops autoimmune hypothyroidism, making it genuinely unpredictable. The researchers flagged one practical warning sign: patients who keep needing their levothyroxine dose reduced during follow-up may be producing stimulating antibodies that are quietly shifting the balance. They recommended testing for TSH receptor antibodies in those patients.2PubMed. Transition from Hashimoto thyroiditis to Graves’s Disease: an unpredictable change?
Hashitoxicosis Is Not the Same Thing
Before assuming a switch to Graves’ disease, doctors first consider hashitoxicosis, which is something quite different. This is a transient hyperthyroid phase that occurs within Hashimoto’s thyroiditis itself, typically early in the disease. As the immune system destroys thyroid cells, stored hormones spill into the bloodstream and temporarily drive levels up. It looks like hyperthyroidism on lab work, and the person can feel the symptoms: racing heart, anxiety, tremor, heat intolerance.
The key distinction is that hashitoxicosis is self-limiting. The hyperthyroid phase usually lasts one to two months before the person settles into the hypothyroid pattern that defines Hashimoto’s long term.3PubMed Central. Prolonged Duration of Hashitoxicosis in a Patient with Hashimoto’s Thyroiditis: A Case Report and Review of Literature During this window, treatment is supportive rather than aggressive. Anti-thyroid medications are usually unnecessary because the gland is not overproducing hormones; it is simply leaking what it had stored. The distinction matters because misidentifying hashitoxicosis as Graves’ disease could lead to treatments that worsen the eventual hypothyroidism.
The Antibody Seesaw
Some of the most puzzling cases involve patients whose thyroid function oscillates, swinging from underactive to overactive and back again over the course of months or years. This is not a one-time conversion but a recurring pendulum, and it is driven by competing antibodies that take turns dominating.
The mechanism involves two types of antibodies with opposite effects on the TSH receptor. Thyroid-stimulating autoantibodies push the gland into overdrive. TSH-blocking autoantibodies do the reverse, preventing the gland from responding to its normal hormonal signals and causing hypothyroidism. In some patients, the relative concentrations, binding strengths, or potencies of these antibodies shift over time. Anti-thyroid drugs used to treat hyperthyroidism can suppress the stimulating antibodies enough for the blocking ones to dominate, tipping the patient into hypothyroidism. Conversely, levothyroxine given for hypothyroidism may allow stimulating antibodies to re-emerge and overpower the blockers.4PubMed Central. Thyrotropin-blocking autoantibodies and thyroid-stimulating autoantibodies: potential mechanisms involved in the pendulum swinging from hypothyroidism to hyperthyroidism or vice versa
A clinical review documented this alternating pattern specifically, describing how methimazole and levothyroxine themselves appeared to trigger the swings between blocking and stimulating antibody dominance.5Journal of community hospital internal medicine perspectives. Oscillating hypothyroidism and hyperthyroidism – a case-based review Another report confirmed the phenomenon, highlighting fluctuating thyroid function driven by shifts in thyroid-stimulating immunoglobulin and TSH receptor antibodies.6AACE Clinical Case Reports. Alternating Thyroid Status Between Thyrotoxicosis and Hypothyroidism in a Patient with Varying Antithyroid Antibodies
This seesaw pattern is rare, but when it happens, it creates a management headache. The treatment for one state can trigger the other. If you are on levothyroxine and your doctor keeps having to reduce or stop it because your thyroid levels keep creeping up, and then you go back to being hypothyroid once the medication is stopped, this oscillating pattern may be what is happening.
When Medication Creates the Problem
The most common reason a person with hypothyroidism ends up with hyperthyroid symptoms has nothing to do with autoimmune shifts. It is simply taking too much levothyroxine. This iatrogenic (treatment-caused) hyperthyroidism ranges from subtle to serious.
At the mild end sits subclinical hyperthyroidism, where TSH is suppressed but thyroid hormone levels are technically within the normal range. The person may feel fine, but research has linked this state to measurable effects including changes in heart function, elevated liver enzymes, and reduced bone density.7PubMed. Subclinical hyperthyroidism: possible danger of overzealous thyroxine replacement therapy At the severe end, levothyroxine over-replacement has been associated with Takotsubo cardiomyopathy, a stress-induced heart condition, underscoring why dose adjustments matter, especially in patients with cardiovascular risk factors.8PubMed Central. Levothyroxine Dose Adjustment to Optimise Therapy Throughout a Patient’s Lifetime
Dose needs change over a lifetime. Weight gain or loss, aging, pregnancy, new medications, and changes in absorption can all shift how much levothyroxine your body actually uses. A dose that was perfect two years ago may now be too high, particularly if you have lost weight, gone through menopause, or started taking supplements at a different time of day. Regular TSH monitoring catches this, but patients who skip follow-up blood work for long stretches are the ones most vulnerable to drifting into over-replacement.
Iodine Exposure as a Trigger
Iodine is the raw material the thyroid uses to make hormones, and for most people, the gland has a built-in safety switch that prevents overproduction when iodine intake spikes. But in people with pre-existing thyroid conditions, that regulatory mechanism can fail. This is known as iodine-induced hyperthyroidism, sometimes called the Jod-Basedow phenomenon.
The most common clinical scenario involves a patient with underlying thyroid disease who receives iodinated contrast dye for a CT scan or cardiac catheterization. A single contrast administration delivers a massive iodine load, and in a susceptible thyroid, the gland escapes its normal autoregulation and begins pouring out excess hormones. The consequences can be severe, including arrhythmias, heart failure, and blood clots.9PubMed Central. A Thyrotoxicosis Surprise: Jod-Basedow Phenomenon Following IV Contrast Administration
If you have hypothyroidism and are scheduled for any procedure involving iodine-based contrast, this is worth mentioning to your doctor. The risk is not universal, but people with nodular goiters or underlying autoimmune thyroid disease are more vulnerable. Some physicians will check thyroid function before and after contrast administration in at-risk patients.
How Doctors Figure Out What Is Going On
When someone known to be hypothyroid suddenly develops hyperthyroid lab values, the clinical question is: why? The answer determines treatment, and blood tests are the primary tool for sorting it out.
The first step is confirming hyperthyroidism itself, which shows up as a suppressed TSH with elevated free T4 and free T3. After that, antibody testing becomes the detective work. TRAb (TSH receptor antibodies) is the single most useful marker for distinguishing Graves’ disease from other causes. Untreated Graves’ disease shows a positive TRAb rate of about 98%, and Graves’ patients have significantly higher TRAb levels than Hashimoto’s patients. Meanwhile, Hashimoto’s patients tend to show much higher levels of anti-TPO and anti-Tg antibodies.10PubMed Central. A Review of Testing for Distinguishing Hashimoto’s Thyroiditis in the Hyperthyroid Stage and Grave’s Disease
In children, the diagnostic performance of TRAb has been studied directly. One analysis found TRAb had the highest ability to distinguish Graves’ disease from hashitoxicosis, with a cutoff of 2.6 IU/L yielding 100% specificity, meaning that if TRAb was above that level, it was Graves’ every time. Anti-TPO and anti-Tg antibodies, by contrast, performed poorly at making the distinction.11Turkish Journal of Pediatric Disease. Differentiating Graves disease from Hashitoxicosis in children: Clinical and biochemical predictors
Radioactive iodine uptake scans add another layer. In Graves’ disease, the scan shows diffusely increased uptake because the entire gland is being stimulated. In hashitoxicosis, uptake is low because the gland is not actively making hormones; it is just leaking stored ones. In iodine-induced hyperthyroidism, uptake is also low. And in levothyroxine over-replacement, uptake is suppressed because the body’s own thyroid production has been shut down by the external supply. The combination of blood work and imaging usually gives a clear answer.
The Conversion in Children
The Hashimoto’s-to-Graves’ switch is not limited to adults. Pediatric cases have been documented, and they present a particular challenge because thyroid dysfunction in growing children can affect development, growth, and school performance.
Two reported pediatric cases illustrate the range. A 10-year-old girl who had been hypothyroid for three years on levothyroxine developed fatigue, goiter, and rapid weight loss of about 3 to 4 kilograms per month. Lab work confirmed free T4 at 3.3 ng/dL (well above normal) with a TSH of 0.005, essentially zero. Her TBII (a measure of TSH receptor antibodies) was strongly positive at 3.07 IU/L. She was started on methimazole and propranolol for Graves’ disease. An 11-year-old girl followed a faster course, converting from Hashimoto’s hypothyroidism to Graves’ disease within just a few months of starting levothyroxine, with TBII skyrocketing to 34.37 IU/L.12International Journal of Thyroidology. Progression of Hashimoto’s Thyroiditis to Graves’ Disease: a Report of Two Pediatric Cases
For parents of children with Hashimoto’s, the takeaway is not to panic but to stay attentive. If a child on thyroid replacement develops new symptoms like unexplained weight loss, rapid heartbeat, or worsening school concentration, those warrant blood work rather than a dose adjustment based on guesswork.
Cancer Treatment and the Thyroid
A newer and increasingly relevant cause of thyroid status changes comes from immune checkpoint inhibitors, a class of cancer drugs that work by releasing the brakes on the immune system. These medications have revolutionized treatment for melanoma, lung cancer, and several other malignancies, but their immune-activating effects can hit the thyroid as collateral damage.
Research examining checkpoint inhibitor-induced thyroid dysfunction identified two distinct patterns. The more common pattern, seen in 12 out of 16 cases in one study, involved an initial period of hyperthyroidism followed by a decline into hypothyroidism. The hyperthyroid phase was typically mild or even asymptomatic, but the subsequent hypothyroidism usually required ongoing levothyroxine replacement. The less common pattern, seen in the remaining 4 out of 16 cases, involved de novo hypothyroidism without any preceding hyperthyroid phase.13Endocrine Connections. Two distinct clinical patterns of checkpoint inhibitor-induced thyroid dysfunction
This is a slightly different angle on the question. Here, the starting point is not pre-existing hypothyroidism flipping to hyperthyroidism, but rather a drug-induced inflammatory storm in the thyroid that creates a brief hyperthyroid phase before the gland burns out. The biphasic pattern resembles hashitoxicosis on a compressed timeline. If you are undergoing immunotherapy and notice symptoms like heart palpitations, sweating, or unusual anxiety, thyroid function tests can quickly rule this in or out.
Pregnancy and Autoimmune Thyroid Shifts
Pregnancy profoundly rearranges the immune system. The body must simultaneously tolerate a genetically foreign fetus while maintaining defenses against infection. These immune adaptations create a window where autoimmune thyroid disease can be triggered or its character can change.
Autoimmune thyroid disease affects women roughly twice as often as men, with the reproductive years being a particularly high-risk period.14PubMed Central. Autoimmune Thyroid Disease and Pregnancy: The Interaction Between Genetics, Epigenetics and Environmental Factors During pregnancy itself, autoimmune activity tends to calm down as the immune system shifts toward tolerance, which is why some women with Graves’ disease see improvement in their second and third trimesters. The rebound after delivery is the dangerous window: the immune system roars back, and this is when new-onset Graves’ disease or a shift from Hashimoto’s to Graves’ is more likely to surface. Postpartum thyroiditis can also mimic this pattern, with a transient hyperthyroid phase in the first few months after delivery followed by hypothyroidism that may or may not be permanent.
What a Real Case Looks Like
Understanding the clinical reality helps ground the discussion. One documented case described a 56-year-old woman with a history of hypothyroidism who had been taken off levothyroxine after developing thyrotoxic lab values. When evaluated, she had physical signs of Graves’ disease including lid lag and bilateral proptosis (bulging eyes measuring 23 mm). Testing confirmed both thyroid peroxidase antibodies and thyroid-stimulating immunoglobulin, meaning her immune system was running Hashimoto’s and Graves’ simultaneously. After restarting levothyroxine, she developed subclinical hyperthyroidism and the medication was again stopped. She remained euthyroid (normal thyroid function) for a full year off of all medication, then developed mild hyperthyroidism with increased radioactive iodine uptake before eventually normalizing again without treatment.15AACE Clinical Case Reports. Conversion of Hypothyroidism to Hyperthyroidism: A Rare Clinical Phenomenon
That winding course is typical of the autoimmune conversion. The disease is not a clean binary switch from one condition to the other. It often involves periods of apparent normalcy punctuated by flares in one direction or the other, making management a moving target rather than a set-it-and-forget-it protocol.
Treatment When the Thyroid Keeps Changing Direction
Managing a thyroid that oscillates between under- and overactivity is genuinely difficult. Standard treatment for hypothyroidism is levothyroxine; standard treatment for Graves’ hyperthyroidism is anti-thyroid drugs, radioactive iodine, or surgery. But when the same patient alternates between the two states, each treatment can provoke the opposite condition.
Levothyroxine given for a hypothyroid phase may allow stimulating antibodies to emerge, triggering hyperthyroidism. Anti-thyroid drugs given for a hyperthyroid phase may suppress stimulating antibodies enough for blocking antibodies to take over, triggering hypothyroidism.4PubMed Central. Thyrotropin-blocking autoantibodies and thyroid-stimulating autoantibodies: potential mechanisms involved in the pendulum swinging from hypothyroidism to hyperthyroidism or vice versa This cycle is exhausting for patients and frustrating for clinicians.
For patients who continue swinging, definitive therapy is often recommended. This means removing the thyroid entirely through surgery or ablating it with radioactive iodine, eliminating the organ that both sets of antibodies are fighting over.16PubMed Central. Alternating hyperthyroidism and hypothyroidism in Graves’ disease After thyroid removal or ablation, the patient becomes permanently hypothyroid and takes levothyroxine for life, but at least the chaotic swings stop. It sounds counterintuitive to deliberately make someone hypothyroid, but stable hypothyroidism managed with a daily pill is far easier to live with than unpredictable swings between two opposite dysfunctions.
The emphasis on close monitoring comes through in the literature repeatedly. If you have autoimmune hypothyroidism and your levothyroxine needs keep dropping, or if you develop any hyperthyroid symptoms, that is the moment for antibody testing rather than simple dose tinkering.2PubMed. Transition from Hashimoto thyroiditis to Graves’s Disease: an unpredictable change? Catching the shift early gives your doctor more options and prevents complications from prolonged untreated hyperthyroidism, which is harder on the heart and bones than most people realize.